Explore the Agenda
8:00 am Check-In & Coffee
Kick off the final day of the conference with a coffee as you reignite valuable conversations from day one and spark new relationships.
8:55 am Chair’s Opening Remarks
Aligning with Investors to Transform Innovation into Investment
9:00 am Panel Discussion: Uncovering Investor Priorities to Secure Cell Therapy Funding in 2027 & Beyond
- Exploring the differences between European and US investment environments to optimise fundraising strategies
- Understanding the technologies, data packages and business models attracting investment to shape development strategies around evolving investor priorities
- Identifying strategies to differentiate from growing competition and build compelling investment cases that attract capital
- Discussing the future direction of the space to align with biotech innovation
9:45 am Building a First-in-Class CXCR5-Targeting Cell Therapy to Overcome Relapse Through Dual Tumour & Microenvironment Targeting
- Harnessing CXCR5 as a novel therapeutic target to address antigen escape while targeting tumorigenic cells and the tumour microenvironment
- Demonstrating the scientific rationale for CXCR5-directed therapies, including the elimination of both malignant B-cells and CXCR5-expressing TFH cells that contribute to disease persistence
- Sharing the latest preclinical progress across oncology and autoimmune indications and looking to the future for clinical development
10:15 am Morning Break & Networking
Re-engage with highly sought-after investors through pre-arranged 1:1 meetings, deepen discussions around your strategy and funding needs and turn introductions into strategic partnership opportunities.
Preclinical Innovation
Optimising In Vivo Delivery Strategies to Enhance Targeting, Safety & Clinical Translation
11:15 am Designing Selective Multi-Immune Cell Targeting LVVs with No Off-Target Delivery for In Vivo CAR-Ts Against Solid Tumours
- Engineering immune cell-targeted lentiviral vectors to enable selective in vivo CAR-T engineering while minimising offtarget transduction and associated safety risks
- Targeting multiple immune cell types to combat solid tumours
- Advancing a next-generation in vivo platform to broaden patient access to transformative cell therapies
11:45 am Enabling In Vivo Cell Therapies to Combat Solid Tumours
- Exploring the specific challenges raised by solid tumours to in vivo cell therapy
- Designing approaches to all tackle key challenges
- Preclinical data demonstrating in vivo therapies for solid tumours
12:15 pm Panel Discussion: Intelligently Pairing Vectors, Payloads & Engineering Technologies for In Vivo Cell Therapy Success
- Comparing viral and non-viral delivery approaches to understand how vector selection impacts safety, efficacy and cell-specific targeting
- Exploring advances in vector technology to successfully deliver DNA, mRNA and cRNA to unluck more durable expression with decreased therapeutic doses
- Developing scientifically guided frameworks to match delivery platforms, genetic cargo and tumour biology to accelerate translation to the clinic
Clinical & Manufacturing Strategy
Advancing Smarter Manufacturing Strategies to Reduce Costs & Enable Sustainable Growth
11:15 am Building Scalable TCR Manufacturing Strategies to Streamline Clinical Progression
- Designing manufacturing strategies to enable timely implementation/tech transfer of innovations
- Leveraging phase-appropriate automation to balance flexibility and scalability
- Understanding regulatory aspects that impact process design and innovation when progressing to later phases
11:45 am Building Cost-Effective Solutions for Complex Manufacturing Processes
- Identifying the greatest cost drivers across development and manufacturing to proactively build a sustainable path to commercialisation
- Designing flexible manufacturing strategies to enable speed or COGs innovations that don’t disrupt regulatory approval or proof of comparability
- Leveraging established pipelines to utilise similar CAR constructs across indications to reduce manufacturing changes, cost and regulatory push-back
12:15 pm IMA203CD8 in Positive Solid Cancers
- Showcasing the manufacturing strategy behind IMA203 to meet the dosing demands of PRAME-positive solid tumours
- Connecting manufacturing innovation with clinical impact by enabling high-dose TCR therapies for solid tumours and supporting the advancement of emerging clinical data in nextgeneration cell therapies
12:45 pm Lunch Break & Networking
Refuel over lunch while making the most of curated 1:1 meetings, available through our dedicated app. Connect directly with your key contacts and turn introductions into meaningful long-term relationships.
Showcasing Emergent Technologies to Enable In Vivo
1:45 pm Utilising Non-Viral DNA Delivery to Define a Third Path for In Vivo CAR-T Therapies
- Exploring how single-stranded DNA delivery combines the advantages of non-viral manufacturing with the durability required for lasting therapeutic responses
- Showcasing emerging preclinical evidence supporting durable, relapse-resistant CAR-T therapies generated entirely through non-viral approaches
2:15 pm Affinity Conjugation to Enable Personalised & Targeted LNP Delivery for In Vivo CAR Therapy
- Enabling attachment of personalised LNPs at the bedside
- Enhancing potency and efficacy of targeted LNPs to improve payload delivery and minimise off-target exposure
- Leveraging freeze-dried LNPs to simplify storage, distribution, and rapid bedside preparation
- Validated in mouse and NHP studies for both in vivo CAR-T and CAR-M
Exploring Emerging Clinical & Manufacturing Designs to Decrease Unmet Patient Need While Producing Reliable Clinical Data
1:45 pm Introducing Point of Care Manufacturing Opportunities to Expand Patient Access to Cell Therapies
- Identifying the critical success factors for establishing a decentralised manufacturing network, including technology transfer, quality oversight, site readiness and partner selection
- Demonstrating how a point-of-care manufacturing model reduced treatment timelines and expanded patient access through a real-world implementation case study
- Exploring the network of point of care manufacturing
2:15 pm Roundtable Discussion: Evaluating the Role of Hospital Exemptions & Point of Care Manufacturing to Expand Access Beyond Conventional CAR-T
- Exploring how regulations and appetite for both POC and hospital exemptions differ across the region to understand implementation feasibility across Europe
- Evaluating the long-term commercial viability of POC manufacturing, examining whether reduced logistics and turnaround times can outweigh quality control, regulatory and scalability challenges
- Defining what constitutes sufficient clinical evidence to support broader adoption, reimbursement and physician confidence in alternative CAR-T delivery models
2:25 pm Afternoon Networking & C -Level Think Tank
Invitation Only Session
Step inside this closed-door discussion where Europe’s senior executives unite to exchange hardto access market intelligence, benchmark strategies and discuss the opportunities and challenges that will actively define the future of the cell therapy space.
Highlighting Innovations in Solid Tumour Therapies to Combat Unmet Patient Need
3:45 pm Engineering Next-Generation CAR-T Cells for Improved Efficacy in Solid Tumours
- Understanding immune biology to design tumour-specific CAR-T therapies
- Advancing construct innovations to deliver safe and effective outcomes for complex solid tumours
- Sharing emerging clinical data to validate novel solid tumour CAR-T approaches
4:15 pm Unlocking the Potential of TCR-NK Therapy for Solid Tumours
- Harnessing TCR specificity and NK-cell biology to create a differentiated approach to solid tumour targeting
- Reviewing preclinical evidence supporting anti-tumour activity, durability, and translational potential
- Sharing clinical progress and safety findings to highlight the therapeutic potential of TCR-NK therapies in patients